PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods
- PMID: 40127903
- PMCID: PMC11931409
- DOI: 10.1136/bmj-2024-082505
PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods
Abstract
The Prediction model Risk Of Bias ASsessment Tool (PROBAST) is used to assess the quality, risk of bias, and applicability of prediction models or algorithms and of prediction model/algorithm studies. Since PROBAST’s introduction in 2019, much progress has been made in the methodology for prediction modelling and in the use of artificial intelligence, including machine learning, techniques. An update to PROBAST-2019 is thus needed. This article describes the development of PROBAST+AI. PROBAST+AI consists of two distinctive parts: model development and model evaluation. For model development, PROBAST+AI users assess quality and applicability using 16 targeted signalling questions. For model evaluation, PROBAST+AI users assess the risk of bias and applicability using 18 targeted signalling questions. Both parts contain four domains: participants and data sources, predictors, outcome, and analysis. Applicability of the prediction model is rated for the participants and data sources, predictors, and outcome domains. PROBAST+AI may replace the original PROBAST tool and allows all key stakeholders (eg, model developers, AI companies, researchers, editors, reviewers, healthcare professionals, guideline developers, and policy organisations) to examine the quality, risk of bias, and applicability of any type of prediction model in the healthcare sector, irrespective of whether regression modelling or AI techniques are used.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. KGMM is director of Health Innovation Netherlands (HI-NL), editor in chief of BMC Diagnostic and Prognostic Research, and principal investigator and author of the “Guidance for high quality AI in healthcare” (https://guideline-ai-healthcare.com). GSC is director of the UK EQUATOR Centre, editor in chief of BMC Diagnostic and Prognostic Research, and a statistical editor for The BMJ. PL is a meta-researcher with the UK EQUATOR Centre. RR is a statistical editor for The BMJ and receives royalties for two textbooks: Prognosis Research in Healthcare and Individual Participant Data Meta-Analysis.
References
LinkOut - more resources
Full Text Sources